Over the past 5 years, the EMA has approved several of these effective treatments based on specific alterations, regardless of the tumor type, such as larotrectinib and entrectinib for NTRK fusions and selpercatinib for RET fusions.16, 17, 18. Here, RET is linked to neoplasm.